Tumor Characteristic Articles & Analysis
10 news found
SEngine's CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. ...
The Cancer Registry of Norway is one of the oldest and most respected organisations of its kind in the world. It collects data and produces statistics of the cancer prevalence in Norway, has the administrative responsibility for the public screening programme in Norway and has an extensive research activity. In a recent study, the Registry used over 120,000 screening examinations from a ...
“We are excited about the broad potential of BXCL701 to extend the activity of checkpoint therapy into cold tumor settings and look forward to initiating the randomized trial extension in patients with adenocarcinoma and continuing patient enrollment in ...
Live tumor models from a biopsy or surgical resection of a patient’s primary or metastatic brain tumor will be generated at the Dana-Farber Center for Patient Derived Models (CPDM) using methods they have established for maximizing the viability of brain tumor cells. ...
The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session ...
In the case study presented at AACR 2021, the patient’s tumor responded to Ibrutinib, a well-tolerated drug that could potentially help 10% of patients with ovarian ...
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast ...
CTT1403, with its longer circulating time and better tumor targeting characteristics, offers distinct advantages in this treatment arena providing the patient with cost and treatment benefits,” commented Dr. ...
Secondary endpoints included anti-tumor effects and cellular immune response, plus overall survival. To identify immunological and molecular signatures of responses, three serial liver biopsies (before, during, and after virotherapy) allowed for in-depth analyses of pathological tumor characteristics, tumor-infiltrating immune ...